Withus Pharmaceutical

330350 · KOSDAQ · ₩330350 · 위더스제약

₩6,450▲ ₩50 (0.78%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩7,485

vs the current price (₩6,450)

Enterprise value
₩86B
Equity value
₩99B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩3,388
−47.5%
Base
₩7,485
+16.0%
Bull
₩14,829
+129.9%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (6.7%).

Revenue growth

  • 18.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (18.1% a year, annual reports), fading to 3% by year 5.

  • 14.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (18.1% a year, annual reports), fading to 3% by year 5.

  • 10.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (18.1% a year, annual reports), fading to 3% by year 5.

  • 6.8%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (18.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (18.1% a year, annual reports), fading to 3% by year 5.

Business

  • 6.7%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 6.5%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 8.1%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 33.8%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.37, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩112B
Net debt (borrowings and leases − cash and deposits)
−₩1.3B
+ Stakes and investments
₩11B
Associates, long-term financial assets and deposits (book value)
Shares
13,199,680
Share price
₩6,450
Market cap
₩85B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩80B₩103B₩106B₩132B₩151B₩167B₩178B₩183B
Growth23.9%28.2%3.6%18.1%14.3%10.5%6.8%3.0%
EBIT₩7.9B₩5.7B₩5.7B₩8.8B₩10B₩11B₩12B₩12B
EBIT margin9.9%5.5%5.3%6.7%6.7%6.7%6.7%6.7%
After-tax EBIT₩5.7B₩4.1B₩4.1B₩6.4B₩7.3B₩8.1B₩8.6B₩8.9B
+ Depreciation———₩8.6B₩9.8B₩11B₩12B₩12B
− Capital spending₩12B₩6.6B₩3.1B₩11B₩12B₩13B₩14B₩15B
− Working capital−₩7.6B−₩2.1B₩5.2B₩6.8B₩6.4B₩5.4B₩3.8B₩1.8B
Free cash flow———−₩2.5B−₩1.5B₩76M₩2B₩4.2B
Discount factor———0.9310.8670.8070.7510.700
Present value———−₩2.4B−₩1.3B₩62M₩1.5B₩2.9B

Terminal value ₩122B, worth ₩85B today: 99% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩7,874 a share)Now 0.82×₩7,0830.90×₩9,1001.16×₩12,5101.59×
Price / earnings (last 12 months: ₩427 a share)Now 15.1×₩5,14012.0×₩8,40019.7×₩35,15382.3×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩8,382₩8,816₩9,344₩10,003₩10,851
6.9%₩7,598₩7,926₩8,318₩8,795₩9,389
7.4%₩6,939₩7,190₩7,485₩7,836₩8,263
7.9%₩6,378₩6,572₩6,795₩7,058₩7,370
8.4%₩5,896₩6,046₩6,217₩6,414₩6,644

Now (TTM)

Market cap
₩85B
Enterprise value
₩83B
P/E
15.1×
P/B
0.8×
P/S
0.8×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩8,620₩7,040₩9,730₩9,370₩10,500
Market cap₩114B₩93B₩128B₩124B₩139B
P/E22.9×19.4×16.1×49.9×32.5×
P/B1.2×1.0×1.4×1.5×1.7×
P/S1.1×0.9×1.6×1.9×2.4×
EV/EBITDA—————
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Withus Pharmaceutical15.1×0.8×0.8×—0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Withus Pharmaceutical / 위더스제약 / 330350 / KRX:330350

Source: KRX statistical information